Valuation check: ME's ROE is -7.22%, below the Healthcare sector average of 29.39%.
Get informed when a big investor buys or sells
+ Follow-721.75%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
23andMe Holding (ME) currently reports a ROE of -7.22%. That is below the Healthcare sector average of 29.39%. Use the charts on this page to explore 23andMe Holding's ROE history and peer comparisons.
23andMe Holding's ROE of -7.22% is lower than the Healthcare sector average of 29.39%. That is roughly 2555.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but 23andMe Holding's current -7.22% should be judged against Healthcare norms (sector average: 29.39%) and against ME's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -7.22%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.39%. From there, open related valuation or income-statement pages for 23andMe Holding, and consider following ME for alerts when major investors trade the stock.
23andMe Holding is classified in the Healthcare sector. On ROE, it currently shows -7.22% versus a sector average near 29.39%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ME with unrelated industries.